ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) for ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Issues related to DEA quotas of Schedule I and II controlled substances S. 524 (114th Congress): Provisions related to opioid treatment and abuse
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Copyright/Patent/Trademark CPT
Abuse-deterrent opioid exclusivity policy issues H.R. 2025, provisions related to abuse-deterrent opioid exclusivity
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Medicare/Medicaid MMM
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Health Issues HCR
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.